Literature DB >> 22434099

Comparative analysis of tumor-infiltrating lymphocytes in a syngeneic mouse model of oral cancer.

Nancy P Judd1, Clint T Allen, Ashley E Winkler, Ravindra Uppaluri.   

Abstract

OBJECTIVE: To perform a comparative analysis of infiltrating immune cells in a newly developed C57BL/6 background syngeneic transplantable mouse oral cancer (MOC) model. STUDY DESIGN/
SETTING: Scientific study in an academic medical center.
METHODS: Use of carcinogen-induced tumorigenesis, tissue culture, cell line transplantation, and flow cytometric analysis techniques.
RESULTS: Previously, the authors established a series of cell line models that displayed dichotomous growth phenotypes when transplanted into immunocompetent mice. They now show that the indolent growth pattern of the MOC1-generated tumors is associated with increased baseline and inducible major histocompatibility complex class I expression and increased CD8(+) T-cell infiltration into the tumor microenvironment. Conversely, the aggressive and metastatic pattern of MOC2-generated tumors has decreased basal and inducible class I expression and is associated with FOXP3(+)CD4(+) regulatory T-cell infiltration. Delayed primary tumor growth after targeted monoclonal antibody therapy of these FOXP3(+) regulatory cells further suggests that these immune cells contribute to the aggressive phenotype of MOC2.
CONCLUSION: These data validate that key infiltrating immune cells identified here parallel findings in human head and neck cancer, making this newly developed syngeneic model a critical platform for the continued dissection of tumor-host interactions in head and neck cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22434099      PMCID: PMC6346425          DOI: 10.1177/0194599812442037

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  37 in total

1.  HPV16 E5 Mediates Resistance to PD-L1 Blockade and Can Be Targeted with Rimantadine in Head and Neck Cancer.

Authors:  Sayuri Miyauchi; P Dominick Sanders; Kripa Guram; Sangwoo S Kim; Francesca Paolini; Aldo Venuti; Ezra E W Cohen; J Silvio Gutkind; Joseph A Califano; Andrew B Sharabi
Journal:  Cancer Res       Date:  2019-12-17       Impact factor: 12.701

2.  Syngeneic Mouse Models of Oral Cancer Are Effectively Targeted by Anti-CD44-Based NIR-PIT.

Authors:  Tadanobu Nagaya; Yuko Nakamura; Shuhei Okuyama; Fusa Ogata; Yasuhiro Maruoka; Peter L Choyke; Clint Allen; Hisataka Kobayashi
Journal:  Mol Cancer Res       Date:  2017-09-18       Impact factor: 5.852

3.  Anti-tumor immunity induced by ectopic expression of viral antigens is transient and limited by immune escape.

Authors:  Neeraja Dharmaraj; Stacey L Piotrowski; Chen Huang; Jared M Newton; Leonard S Golfman; Aurelie Hanoteau; Sandeep T Koshy; Aileen W Li; Merlyn X Pulikkathara; Bing Zhang; Jared K Burks; David J Mooney; Yu L Lei; Andrew G Sikora; Simon Young
Journal:  Oncoimmunology       Date:  2019-02-06       Impact factor: 8.110

4.  Pools of programmed death-ligand within the oral cavity tumor microenvironment: Variable alteration by targeted therapies.

Authors:  Sujay Shah; Andria Caruso; Harrison Cash; Carter Van Waes; Clint T Allen
Journal:  Head Neck       Date:  2016-04-09       Impact factor: 3.147

5.  Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration.

Authors:  Ayman Oweida; Mohammad K Hararah; Andy Phan; David Binder; Shilpa Bhatia; Shelby Lennon; Sanjana Bukkapatnam; Benjamin Van Court; Nomin Uyanga; Laurel Darragh; Hyun Min Kim; David Raben; Aik Choon Tan; Lynn Heasley; Eric Clambey; Raphael Nemenoff; Sana D Karam
Journal:  Clin Cancer Res       Date:  2018-07-24       Impact factor: 12.531

6.  Automated in vivo Assessment of Vascular Response to Radiation using a Hybrid Theranostic X-ray Irradiator/Fluorescence Molecular Imaging System.

Authors:  Farouk Nouizi; Jamison Brooks; Darren M Zuro; Srideshikan Sargur Madabushi; Dayson Moreira; Marcin Kortylewski; Jerry Froelich; Lydia M Su; Gultekin Gulsen; Susanta K Hui
Journal:  IEEE Access       Date:  2020-05-15       Impact factor: 3.367

7.  Enhanced Tumor Control with Combination mTOR and PD-L1 Inhibition in Syngeneic Oral Cavity Cancers.

Authors:  Ellen C Moore; Harrison A Cash; Andria M Caruso; Ravindra Uppaluri; James W Hodge; Carter Van Waes; Clint T Allen
Journal:  Cancer Immunol Res       Date:  2016-04-13       Impact factor: 11.151

8.  Galectin-1-driven T cell exclusion in the tumor endothelium promotes immunotherapy resistance.

Authors:  Dhanya K Nambiar; Todd Aguilera; Hongbin Cao; Shirley Kwok; Christina Kong; Joshua Bloomstein; Zemin Wang; Vangipuram S Rangan; Dadi Jiang; Rie von Eyben; Rachel Liang; Sonya Agarwal; A Dimitrios Colevas; Alan Korman; Clint T Allen; Ravindra Uppaluri; Albert C Koong; Amato Giaccia; Quynh Thu Le
Journal:  J Clin Invest       Date:  2019-12-02       Impact factor: 14.808

9.  P2Y2 receptors mediate nucleotide-induced EGFR phosphorylation and stimulate proliferation and tumorigenesis of head and neck squamous cell carcinoma cell lines.

Authors:  Lucas T Woods; Kimberly J Jasmer; Kevin Muñoz Forti; Vinit C Shanbhag; Jean M Camden; Laurie Erb; Michael J Petris; Gary A Weisman
Journal:  Oral Oncol       Date:  2020-06-12       Impact factor: 5.337

10.  Biomaterial-Facilitated Immunotherapy for Established Oral Cancers.

Authors:  David G Leach; Neeraja Dharmaraj; Tania L Lopez-Silva; Jose Rodriguez Venzor; Brett H Pogostin; Andrew G Sikora; Jeffrey D Hartgerink; Simon Young
Journal:  ACS Biomater Sci Eng       Date:  2021-01-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.